Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 11, 2013, Pages 1529-1536

  Hostler, Christopher J ^a   Chen, Luke F ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adult; Antibacterial agents; Clostridium difficile; Drug therapy; Efficacy; Fidaxomicin; OPT 80; Prophylaxis; Review; Safety

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

ABDOMINAL PAIN; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHEMICAL STRUCTURE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLONIC SECRETION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAND WASHING; HEADACHE; HEALTHCARE ASSOCIATED INFECTION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INSOMNIA; INTESTINE ABSORPTION; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; RECURRENT INFECTION; RNA SYNTHESIS; SECONDARY PREVENTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS;

EID: 84880130036     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.802307     Document Type: Article

References (46)

1. Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011;32(4):387-90
2. Tillotson GS, Tillotson J. Clostridium difficile-a moving target. F1000 Med Rep 2011;3:6
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Cmaj 2004;171(5):466-72
4. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, HCUP statistical brief no. US Department of Health and Human Services, Agency for Healthcare Research and Quality; Rockville, MD: 2011
5. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Eng J Med 2008;359(18):1932-40
6. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterol 2009;136(6):1913
7. Popoff MR, Rubin E, Gill D, et al. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988;56(9):2299-306
8. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Eng J Med 2005;353(23):2442-9
9. Sirard S, Valiquette L, Fortier LC. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 2011;49(12):4040-6
10. Merrigan M, Venugopal A, Mallozzi M, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010;192(19):4904-11
11. Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010;10(6):395-404
12. The U.S. Food and Drug Administration (FDA). Anti-Infective Drug Advisory Committee Meeting Briefing Document April 5 Available from, http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM249354.pdf.
13. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
14. Zar FA, Bakkanagari SR, Moorthi K, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7
15. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec. Canada. Clin Infect Dis 2005;40(11):1591-7
16. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31
17. Musgrave CR, Bookstaver PB, Sutton SS, et al. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011;15(7):e438-48
18. Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010;8(5):555-64
19. Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62(5):1046-52
20. Spigaglia P, Barbanti F, Mastrantonio P, et al. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011;66(10):2227-34
21. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407-15
22. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012;307(18):1959-69
23. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol 2013;6(1):53-68
24. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15(6):274-80
25. D'Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324(7350):1361
26. Johnson S, Maziade P-J, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? International J Infect Dis 2012;16(11):e786-e92
27. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of lactobacillus acidophilus cl1285 and lactobacillus casei LBC80R for antibiotic-associated diarrhea and clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105(7):1636-41
28. Johnson S, Homann SR, Bettin KM, et al. Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole: a Randomized, Placebo-controlled Trial. Ann Intern Med 1992;117(4):297-302
29. Brown KA, Khanafer N, Daneman N, et al. Antibiotics and the risk of community-associated Clostridium difficile infection (CDI): a meta-analysis. Antimicrob Agents Chemother 2013;[Epub ahead of print]
30. Erb W, Zhu J. From natural product to marketed drug: the tiacumicin odyssey. Nat Prod Rep 2013;30(1):161-74
31. Srivastava A, Talaue M, Liu S, et al. New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr Opin Microbiol 2011;14(5):532-43
32. Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):261-3
33. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48(12):4898-902
34. Biedenbach DJ, Ross JE, Putnam SD, et al. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 2010;54(5):2273-5
35. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010;156(Pt 11):3354-9
36. Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 2011;9(7):767-77
37. Miller M. Fidaxomicin (OPT-80) for the treatment of clostridium difficile infection. Expert Opin Pharmacother 2010;11(9):1569-78
38. Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 2012;55(Suppl 2):S127-S31
39. Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012;55(suppl 2):S143-S48
40. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-8
41. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12(4):281-9
42. The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients. Washington University School of Medicine. Available from: http://clinicaltrials.gov/ct2/show/NCT01552668-term = fidaxomicin&rank = 1
43. Safety and efficacy of fidaxomicin versus placebo for prophylaxis against clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation (DEFLECT-1). 2012.Available from: http:// clinicaltrials. gov/ct2/show/NCT01691248-term = fidaxomicin&rank=3
44. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52(11):4163-5
45. Mullane KM, Miller MA, Weiss K, et al. Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections. Clin Infect Dis 2011;53(5):440-7
46. Linsky A, Gupta K, Hermos JA. Fidaxomicin for Clostridium difficile infection. N Engl J Med 2011;364(19):1875; author reply 75-6